Niagen Bioscience (NAGE) appoints Dr. Pinchas Cohen to SAB

Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, is pleased to announce the appointment of Dr. Pinchas Cohen to its Scientific Advisory Board (SAB).​

Dr. Cohen is an internationally recognized leading expert in healthy aging and mitochondrial biology. He serves as Dean of the University of Southern California (USC) Leonard Davis School of Gerontology and is a Distinguished Professor of Gerontology, Medicine, and Biological Sciences. He is internationally renowned for pioneering the field of mitochondrial microproteins—newly discovered therapeutic targets for diseases of aging—and has published over 350 scientific papers in top scientific journals focusing on aging, dementia, cancer, diabetes, and the emerging science of microproteins.

Rob Fried, CEO of Niagen Bioscience, remarked, "We are excited to learn from one of the great minds in mitochondrial and longevity research.”

His most recent discoveries include the novel microproteins MOTS-c, SHLP, SHMOOSE, and MASL, which represent promising precision-medicine solutions for aging-related diseases in diverse populations. Dr. Cohen is also the founder of the Southern California Aging Research Consortium and two biotech companies, CohBar and MENTSH Therapeutics. His many accolades include the National Institutes of Health (NIH) Director’s Transformative Research Award, the Glenn Award for Research in Biological Mechanisms of Aging, and election to both the American Association for the Advancement of Science (AAAS) and the National Academy of Inventors.

Dr. Cohen expressed enthusiasm about the role, noting, "I am honored to join Niagen Bioscience's Scientific Advisory Board. The company's commitment to rigorous scientific research in the field of NAD+ and its impact on aging and metabolic health is truly commendable. I look forward to contributing to their ongoing efforts to enhance healthspan through innovative approaches."​

Niagen Bioscience remains dedicated to collaborating with leading scientists to further its mission of improving human health through cutting-edge NAD+ research.

You May Also Be Interested In

• Lexaria receives $2.6M tax rebate from Australian R&D program
• Sonos launches OS 27 with AI control and two new products
• Snowflake (SNOW) call put ratio 1.3 calls to 1 put into quarter results